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Humans express at least two distinct b-glucuronidase enzymes that are involved in disease: exo-acting b-glucuronidase (GUSB), 
whose deficiency gives rise to mucopolysaccharidosis type VII, and endo-acting heparanase (HPSE), whose overexpression is 
implicated in inflammation and cancers. The medical importance of these enzymes necessitates reliable methods to assay their 
activities in tissues. Herein, we present a set of b-glucuronidase-specific activity-based probes (ABPs) that allow rapid and quan-
titative visualization of GUSB and HPSE in biological samples, providing a powerful tool for dissecting their activities in normal and 
disease states. Unexpectedly, we find that the supposedly inactive HPSE proenzyme proHPSE is also labeled by our ABPs, leading to 
surprising insights regarding structural relationships between proHPSE, mature HPSE, and their bacterial homologs. Our results 
demonstrate the application of b-glucuronidase ABPs in tracking pathologically relevant enzymes and provide a case study of how 
ABP-driven approaches can lead to discovery of unanticipated structural and biochemical functionality. 
  
Retaining  β-glucuronidases  are  enzymes  responsible  for 
hydrolytic cleavage of β-linked glucuronides from polysac-charide and 
glycoconjugate molecules, with net retention of stereochemistry at the 
anomeric center of the released glucuronide. Humans express at least two 
major retaining β-glucuronidases: exo-acting GUSB, responsible for 
cleaving β-linked glucuronides from the nonreducing end of diverse 
glycosaminoglycans (GAGs) in the lysosome, and endo-acting HPSE, 
specifically responsible for the breakdown of heparan sulfate (HS) in 
lysosomes and in the extracellular matrix (ECM). Both enzymes are 
strongly implicated in disease processes: deficiency of GUSB is the basis 
of the auto-somal recessive disease mucopolysaccharidosis type VII 
(MPSVII), also known as Sly syndrome1–3, whereas overexpression of 
HPSE is linked to a variety of pathologies including inflammation and 
cancer metastasis4,5. 
Although both GUSB and HPSE possess β-glucuronidase activ-
ity, these enzymes are dissimilar at the sequence level and fall under 
different families of the Carbohydrate Active enZymes (CAZy) clas-
sification scheme6: GUSB in GH2 and HPSE in GH79. Structurally, 
human GUSB is a large, homotetrameric assembly, with each pro-
tomer comprising a (β/α)8 barrel domain, a jelly roll domain and an 
immunoglobulin-constant-chain-like domain7. By contrast, HPSE is 
a heterodimer containing 8 kDa and 50 kDa subunit chains that fold 
to produce a (β/α)8 barrel flanked by a smaller β-sandwich domain8. 
The mature HPSE heterodimer is formed by proteolytic removal of a 
6-kDa linker peptide from a single-chain proenzyme—proHPSE.  
Given the importance of β-glucuronidases in human health 
and disease, a facile method to visualize and quantitate their 
activity would be of great utility. We have previously reported 
the devel-opment of ABPs based upon the cyclophellitol 
aziridine scaffold, which can be used to specifically detect 
enzymatic activity for a range of glycosidases9–14. These probes 
provide valuable tools to rapidly determine enzyme activities 
within their native physiologi-cal contexts.  
 
Herein, we unveil the synthesis of ABPs designed to selectively 
target and label retaining β-glucuronidases. We demonstrate the 
utility of these probes in quantitating β-glucuronidase activity in a 
range of cell and tissue samples, via both fluorescence and chemi-cal 
proteomics approaches. Unexpectedly, we find that a mono-sugar β-
glucuronidase ABP is sufficient to label not only exo-acting GUSB, 
but also endo-acting HPSE, despite the ABP binding just one of 
multiple subsites within the HPSE active site cleft. Furthermore, the 
supposedly inactive proHPSE proenzyme is also labeled by ABPs, 
prompting us to investigate the nature of proHPSE ‘inacti-vation’ by 
its 6-kDa linker and how the proHPSE structure relates to other 
GH79 enzymes. Our results demonstrate a wide-ranging potential of 
β-glucuronidase ABPs as biological and biomedical tool compounds 
and highlight the general power of ABPs in driving the discovery of 
new biological insights15. 
 
RESULTS 
Glucuronidase-specific inhibitor and probe design 
We have previously demonstrated that cyclophellitol-derived epox-
ides and aziridines are powerful mechanism-based inhibitors for 
retaining β-glucosidases16, owing to their ability to specifically label 
the enzyme catalytic nucleophile in a conformation resembling the 
covalent intermediate of glycoside hydrolase reactions. (Fig. 1a,b)17. 
Inhibition is typically tolerant of functionalization at the ring nitro-
gen of cyclophellitol aziridines, allowing fluorophore or biotin tag-
ging to create inhibitor probes that can label specific glycosidases 
within complex biological mixtures18.  
Conceptually, we envisioned that β-glucuronidase-specific ABPs 
could be accessed from cyclophellitol by oxidation at the C6-
equivalent position to emulate the carboxylate of glucuronic acid 
(GlcUA). ABPs 1–4 are composed of such a β-glucuronide-
configured cyclophellitol aziridine, bearing a spacer from the aziri-
dine nitrogen terminating in boron-dipyrromethene (BODIPY)-FL, a 
BODIPY-TMR analog, Cy5, or biotin, respectively. Alongside 
 
 
1York Structural biology laboratory, department of chemistry, university of York, Heslington, York, uK. 2department of bioorganic Synthesis, leiden 
institute of chemistry, leiden university, leiden, the netherlands. 3department of Medical biochemistry, leiden institute of chemistry, leiden university, 
leiden, the netherlands. 4these authors contributed equally to this work. *e-mail: gideon.davies@york.ac.uk or h.s.overkleeft@chem.leidenuniv.nl 
 
 NATURE cHEmIcAL BIOLOGy  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
Acid/base 
        b    
               
 
O 
 
O 
 
O O 
 
HO O O O 
 
 H     
H 
      H    
               
XH 
 
O 
     
O 
 
O 
    X   
O R 
  
H OH 
      
  
O 
      
    
O
–
    O 
   
 O– O  O    O   O– O  OO 
Nucleophile             Trapped probe 
c HO      HO    –O O    
   6                
HO 
5 
   HO   HO     
N  N  4 7  
O 
 
NH 
         
 
3 2 1 
      
N 
 
N 
 
            
HO     HO   HO      R 
  OH   OH      OH    
Cyclophellitol Cyclophellitol   β-Glucuronidase ABP    
       aziridine            
1: R =      2: R =  3: R =    N+    
         HN       
            O     
N 
 
                  
 N
+ 
 N  N
+ 
– N            
 B–     B            
 F F    F F 4: R = 
O 
    
HN 
O 
          H   
          N   N    NH 
      
MeO OMe 
  H     
S 
 
        
O 
  
             
               
–O O       –O O     –O    O  
HO        HO       HO  
   N  N3     NH     O  
HO        HO       HO  
 OH         OH     OH  
 5         6      7   
 
Figure 1 | concept and design of b-glucuronidase-targeting ABPs. (a) 
Generalized schematic of the double-displacement mechanism employed 
by retaining β-glycosidases. (b) Mechanism-based inhibition by 
cyclophellitol-derived Abps. (c) Structures of cyclophellitol-, cyclophellitol-
aziridine-, and β-glucuronidase-specific Abps used in this study. 
numbering of atomic positions is shown on cyclophellitol. 
 
these functionalized ABPs, we also prepared azide-substituted 
ABP (5; the precursor of 1–4), unsubstituted aziridine (6) and 
cyclophellitol-6-carboxylate (7) (Fig. 1c; structures of additional 
compounds 8–16 used in this study are shown in 
Supplementary Results, Supplementary Fig. 1). 
 
GlcUA ABPs target b-glucuronidases in vitro and in situ  
To assess the potency of our β-glucuronidase ABPs in vitro, we first 
turned to the exo-acting GH79 β-glucuronidase AcGH79 from 
Acidobacterium capsulatum, whose activity is readily followed 
using the fluorogenic substrate 4-methylumbelliferylglucuronic acid 
(4MU-GlcUA)19. All compounds tested were effective inhibitors of 
AcGH79, with apparent half-maximum inhibitory concentrations 
(IC50s) in the low-to-subnanomolar range (Table 1, left panel). Core 
ABP ‘warhead’ 6 inhibited AcGH79 with an apparent IC50 of ~5 
nM. This was potentiated by further functionalization: apparent IC50 
of Cy5-substituted ABP 3 was ~1 nM, whereas 1, 2, 4 and 5 were all 
subnanomolar inhibitors of AcGH79. Apparent IC50 for epoxide 7 
was ~34 nM, consistent with lower reactivity of the epoxide moiety 
compared to aziridines.  
Kinetic parameters for inhibition of AcGH79 were determined 
using a continuous assay, in which substrate and inhibitor react with 
enzyme simultaneously (Supplementary Note 1)20, allowing us to 
derive a combined inhibition parameter ki/KI for all ABPs tested. 
ki/KI values largely reflected the trend seen for the IC50s, with the 
activity of core aziridine 6 potentiated by further functionalization 
and epoxide 7 found to be substantially less active than aziridines 
(Table 1, middle panel; Supplementary Fig. 2).  
Finally, we tested the ability of our probes to inhibit β-
glucuronidases in live fibroblast cells. In situ apparent IC50s for 
ABPs 2 and 3 were determined to be in the low-micromolar range 
 
 
Table 1 | Apparent Ic50 values and kinetic parameters 
for b-glucuronidase inhibition by ABPs 
 
 In vitro   In situ 
 acGH79 Kinetic parameters fibroblast 
 apparent IC50 (acGH79) apparent 
Compound (nM) ki/KI (mM–1min−1) IC50 (mM) 
1 0.6 ± 0.2 25.0 ± 0.7 >15 
2 0.8 ± 0.2 18.2 ± 0.9 1.7 ± 0.6 
3 1.1 ± 0.1 14.0 ± 0.8 1.8 ± 0.4 
4 0.4 ± 0.02 5.5 ± 0.2 >15 
5 0.1 ± 0.01 18.8 ± 0.7 >15 
6 4.6 ± 0.03 3.5 ± 0.2 >15 
7 33.4 ± 3.1 0.49 ± 0.05 >15  
All data shown are mean values  s.d. (N = 3). Replicates for in situ fibroblast inhibition are 
biological replicates from three independent cell culture experiments treated with inhibitor. 
 
(~1.7 and ~1.8 μM, respectively). We were unable to determine 
in situ apparent IC50s for 1 or 4–7, likely reflecting a limited 
ability of these compounds to permeate the cell membrane 
(Table 1, right panel).  
Fluorescence labeling of AcGH79 by ABP 1 was readily visu-
alized by SDS–PAGE, and could be blocked by competition with 
2–7, 4MU-GlcUA, or iminosugar 8. Labeling was also abolished 
by SDS denaturation of protein, a result in line with a 
mechanism-based mode of action requiring catalytically 
competent enzyme (Supplementary Fig. 3a).  
To dissect the mechanistic mode of action of our probes, we 
obtained crystal structures of 5 in complex with wild-type AcGH79 
and in complex with an inactive AcGH79(E287Q) nucleophile 
mutant (Supplementary Fig. 3b,c). Both complexes showed a 
single molecule of 5 bound within the active site of AcGH79, with 
no labeling of off-target residues. In wild-type AcGH79, reacted 5 
was observed to be bound via C1 to the enzyme nucleophile 
(Glu287) in a 4C1 conformation, making noncovalent contacts 
identical to those previously observed for GlcUA or 2F-GlcUA19. In 
the AcGH79(E287Q) mutant, 5 occupied the same active site 
position, but was found to adopt a 4H3 conformation as a result of 
restricted rotation across the C1–C7 bond imposed by the aziridine. 
Notably, the 4H3 conformation observed for unreacted 5 is the same 
as that postulated for oxocarbenium-like transition states of retain-
ing β-glycosidase substrates during hydrolysis (Supplementary Fig. 
3d)21. The high affinities of cyclophellitol-derived ABPs for their 
target enzymes may partially derive from their conformational 
mimicry of this transition state22. 
 
ABP profiling reveals GUSB and HPSE as probe targets  
To determine the targets of retaining β-glucuronidase ABPs in 
complex biological samples, human splenic lysates (which we have 
previously shown to express a range of glycosidases10,12) were treated 
with one or more ABPs and resolved by SDS–PAGE. Labeled pro-
teins were then visualized by fluorescence scanning (the typical 
ABP workflow is shown in Supplementary Fig. 4). 
Several fluorescent bands were observed in samples treated with 
Cy5 ABP 3 that were absent in a mock (DMSO) control and that 
could be competed for by biotin ABP 4 (Fig. 2a). Based on litera-
ture reports, we tentatively assigned the prominent double bands at 
~78–80 kDa as full-length and C-terminal-truncated isoforms of 
GUSB23 and the lowest-molecular-weight band as the ~64-kDa iso-
form of GUSB24; these bands were also identified by an anti-GUSB 
western blot (Supplementary Fig. 5a). A band at ~60 kDa did not 
correspond with any known glucuronidases, but could be abrogated 
by pretreatment with β-glucosidase ABP 9, suggesting that this was 
the lysosomal acid β-glucosidase GBA, which is specifically labeled 
 
 
NATURE cHEmIcAL BIOLOG  
 
by 9 (ref. 12). Correspondingly, this ~60-kDa band was also 
absent in splenic lysates from patients with Gaucher disease, 
which is char-acterized by lack of GBA activity. 
To unambiguously establish the targets of our ABPs, we carried 
out a set of chemical proteomics experiments using LC–MS/MS. 
Lysates from normal or Gaucher spleens were incubated with biotin 
ABP 4 with or without pretreatment using 9. Labeled proteins were 
then pulled down using streptavidin beads and processed by a stan-
dard proteomics workflow using both ‘in-gel’ and ‘on-bead’ digest 
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protocols (Supplementary Fig. 4). The ‘on-bead’ digest 
protocol was also applied to human fibroblast lysates to assess 
the efficacy of ABP pulldown in another tissue type. 
Proteomic profiling using the ‘in-gel’ digest protocol identified 
GUSB as the predominant splenic protein labeled by 4, showing 
particular enrichment in bands corresponding to those previously 
identified fluorescently by 3 (Fig. 2b). In accordance with fluores-
cence labeling results, we detected GBA at ~60 kDa, which was 
abrogated by pretreatment with 9 and reduced in Gaucher spleen. 
‘In-gel’ proteomic results were largely mirrored by those from the 
‘on-bead’ protocol, which showed GUSB to be the most abundant 
glycosidase after pulldown from spleen as well as highly enriched 
after pulldown from fibroblast (Supplementary Data Set 1). 
Covalent modification of the GUSB nucleophile (Glu540) by 4 was 
directly characterized by MS/MS fragmentation of the 13-amino-
acid peptide containing this residue (Supplementary Fig. 5b).  
The high sensitivity of proteomic profiling enabled detection of 
two glycosidase enzymes in splenic lysates that were not observed 
by fluorescence labeling with 3: β-galactosidase GLB1 and endo β-
glucuronidase HPSE. Both enzymes were substantially less abun-
dant in pulldown fractions compared to GUSB, as estimated by their 
exponentially modified protein-abundance-index (emPAI) scores ( 
Supplementary Fig. 5c). We theorized that GLB1 was likely a 
weak nonspecific target of 4, as it showed the lowest emPAI of all 
detected glycosidases despite the robust transcriptional expres-sion 
reported for this protein in spleen (Supplementary Fig. 5d)25 and 
strong histochemical staining of β-galactosidase activity in 
mammalian splenic tissues26. By contrast, HPSE is predicted to be 
poorly expressed in the spleen by transcriptomics, yet showed a 
higher emPAI score than GLB1 after pulldown by 4. These observa-
tions suggested HPSE was a bona fide target of our ABPs, despite 
the inability of the monosugar probes to make a full complement of 
interactions within the HPSE endo-acting substrate cleft, which 
normally accommodates at least a trisaccharide27. 
 
b-glucuronidase ABPs label endogenous HPSE and proHPSE  
Following the surprising discovery that splenic HPSE was 
labeled by 4, we re-examined fluorescence labeling of HPSE in 
cells and tissues expressing higher levels of HPSE. In the first 
instance, we induced HPSE overexpression in HEK293T cells 
and probed harvested lysates at set intervals. Two plasmids were 
tested: pGEn1-HPSE, encoding N-His-Strep-TEV- tagged 
proHPSE, and pGEn2-HPSE, encoding N-His-Avitag-eGFP-
TEV- tagged proHPSE; HEK293T cells subsequently process 
these proHPSE precursors to produce mature HPSE.  
Using 3, we tracked increasing expression of a band at ~50 kDa 
corresponding to the mass of the large HPSE subunit containing the 
nucleophile Glu343 (Fig. 3a)28. Unexpectedly, we also detected 
bands at ~75 kDa for pGEn1-HPSE and at ~100 kDa for pGEn2-
HPSE, corresponding to the masses of proHPSE chains expressed by 
these plasmids. Western blotting using an anti-HPSE antibody 
confirmed these bands to be proHPSE, indicating that 3 also labeled 
the supposedly inactive proenzyme. Initial comparison of band 
intensities from ABP labeling using 3 and western blotting sug-
gested that 3 labeled mature HPSE with greater efficiency than it 
labeled proHPSE. However, the opposite trend was observed when 
using purified recombinant proHPSE (Supplementary Fig. 6a), 
 
Figure 2 | ABP labeling of retaining b-glucuronidases in human spleen 
lysates. (a) three isoforms of GuSb are fluorescently labeled by cy5 Abp 3 in 
human wild-type (wt) spleen, with off-target labeling of the β-glucosidase GbA 
also observed. labeling of these proteins by 3 can be competed for by biotin 
Abp 4. GbA labeling in wild-type spleen is also specifically competed for by 9 
and is absent in lysates from Gaucher spleen. (b) Silver stained SdS–pAGe 
gel of proteins captured from human wild-type spleen by labeling with 4 (with 
or without competition by 9) followed by streptavidin pulldown. Glycosidases 
identified in each gel slice by proteomic profiling are listed. Full proteomics 
data sets for proteins identified by Abp pulldowns are available in 
Supplementary Data Set 1. 
 
suggesting that the majority of proHPSE overexpressed by 
HEK293T cells was likely inactive.  
HPSE maturation is thought to be mediated by the cysteine pro-
tease cathepsin L (CTSL) through multiple proteolytic cleavages of 
the proHPSE 6-kDa linker peptide29. We tested the effect of CTSL 
inhibitors CAA0225 (ref. 30) (10), Z-FY(tBu)-DMK31 (11), and 
leupeptin on proHPSE maturation in HEK293T cells by incubat-ing 
pGEn1-HPSE transfected cells with CTSL inhibitors for 2 d and 
labeling harvested cell lysates with 3. In inhibitor-treated cells, we 
observed modest but dose-dependent accumulation of a band ~5 kDa 
below the principal proHPSE band, corresponding to loss of the 
unstructured N-His-Strep-TEV tag followed by blockade of further 
proteolysis, in line with the role of CTSL in HPSE maturation 
(Supplementary Fig. 6b). However, accumulation of mature HPSE 
was still detected in the presence of all inhibitors tested, suggesting 
either incomplete CTSL inhibition or the presence of non-cathepsin-
mediated HPSE maturation pathways also used by HEK293T cells.  
We also tracked internalization and processing of proHPSE to 
mature HPSE in fibroblasts—a process that may be used by 
cancer cells to increase their own levels of HPSE—by capturing 
and inter-nalizing extracellular proenzyme32. Within 90 min after 
proHPSE was introduced into culture medium, internalization 
and process-ing of HPSE by fibroblasts was detectable using 3 
(Fig. 3b). These experiments demonstrate the ability of β-
glucuronidase ABPs to detect and track key biological processes 
such as HPSE internaliza-tion and maturation.  
Lastly, we re-attempted fluorescence labeling of endogenous HPSE 
in human tissues. As splenic HPSE expression was below the 
fluorescence-detection limit, we turned to platelets, which are known to 
contain high levels of mature HPSE33. Using 3, we observed labeling of 
a band at ~50 kDa in platelet lysates corre-sponding to HPSE in addition 
to the same GUSB bands previously detected in splenic lysates. 
Comparison of fluorescent ABP and western blotting band intensities for 
platelet HPSE and a 200-fmol recombinant HPSE standard suggested 
that fluorescence sensitivity for recombinant HPSE was in the 
femtomole range, and was some-what more sensitive than western 
blotting in our hands. Fluorescent HPSE detection in platelet lysates was 
slightly less sensitive than for the recombinant enzyme, possibly due to 
the presence of competing protein targets or inactive HPSE in situ (Fig. 
3c). Ten nanomoles of 3 was sufficient to produce a detectable HPSE 
signal in platelets after 30 min (Supplementary Fig. 6c). Labeling of 
HPSE, but not of GUSB, was also improved by the addition of NaCl 
(Supplementary Fig. 6d). Optimum labeling of HPSE by 3 was 
achieved at pH 4.5–5.0, consistent with literature reports of its optimum 
pH for enzymatic 
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Figure 3 | Human HPSE is readily visualized by fluorescent b-glucuronidase ABPs. (a) induced overexpression of HpSe and proHpSe in 
HeK293t cells can be tracked by Abp 3. Fluorescence labeling by 3 correlates with bands from western blotting using an anti-HpSe antibody. 
(b) Abp tracking of uptake and processing of proHpSe to HpSe by fibroblast cells. std, standard. (c) endogenous HpSe in human platelets can 
be labeled by 3, along with the same GuSb bands as observed in spleen. (d) pH dependence of HpSe and GuSb labeling in platelet lysates, 
demonstrating how general or specific enzyme labeling can be achieved by modulating pH. 
  
activity34. By contrast, optimum pH for labeling GUSB was higher 
than expected, at pH 5.5–6.0 (Fig. 3d), compared to its reported 
optimum for activity at the lysosomal pH ~4.5 (ref. 35). This unex-
pected pH of GUSB ABP labeling may be due to facile aziridine 
ring opening occurring independently of a protonated acid/base resi-
due36. However, optimum labeling of GUSB at a nonlysosomal pH 
presents its own serendipitous advantages, allowing both GUSB and 
HPSE to be analyzed either jointly or independently of each other 
through modulation of labeling pH. 
 
competitive ABP labeling identifies HPSE-specific inhibitors  
Because ABPs can detect a complete complement of enzymes in a 
cellular or environmental sample, competitive ABP labeling pro-
vides a powerful tool to assess inhibitor efficacy and specificity 
within a single experiment37. We sought to establish whether GlcUA 
ABPs could be used for the assessment of enzyme-specific inhibi-
tors by testing platelet labeling at pH 5.0 (at which both GUSB and 
HPSE react) in the presence of a set of known inhibitors.  
In the presence of the monosaccharide-like β-glucuronidase 
inhibitor siastatin B38, both GUSB and HPSE labeling were abro-
gated in a dose-dependent manner, demonstrating the ability of 
this molecule to outcompete ABP binding in both endo- and exo-
acting enzymes. Using quantitated band intensities, IC50s for 
GUSB and HPSE labeling inhibition were measured to be ~3.3 
μM and ~6.7 μM, respectively, indicating slightly greater 
affinity for GUSB by siastatin B (Fig. 4a). 
By contrast, HPSE labeling in platelets was selectively inhibited 
by competition with heparin (12; IC50 ~ 0.17 mg/ml; Fig. 4b), a 
large polysaccharide that cannot be accommodated by the exo-acting 
active site of GUSB. Selective inhibition was also observed upon 
competition with HS (13), the substrate of HPSE, albeit with slightly 
lower potency (Fig. 4c; IC50 ~ 0.50 mg/ml). Negligible inhibition 
was observed for N-acetyl-O-desulfated heparin (14) 
(Supplementary Fig. 7a), highlighting the importance of sulfation 
for interactions between heparin (or HS) and HPSE. A lower degree 
of sulfation in HS compared to heparin may partly account for its 
slightly weaker abrogation of ABP labeling39.  
We next tested inhibition of labeling by GAGs with different 
link-ages and sulfation patterns to heparin and HS. Hyaluronic acid 
(15) and chondroitin sulfate (16) both showed no inhibition of either 
HPSE or GUSB labeling at concentrations sufficient for inhibition 
by heparin and HS (Supplementary Fig. 7b,c), highlighting the 
critical role of sugar linkage and sulfation in interactions between 
GAGs and HPSE. Taken together, these assays provide proof of 
 
principle that GlcUA ABPs are amenable for use in a 
competitive format to assess inhibition of specific β-
glucuronidases within a mixture of related activities. 
 
Structural basis of HPSE and proHPSE ABP labeling 
To investigate how efficient labeling of endo-acting HPSE was 
achieved by a monosugar ABP, we obtained crystal structures of 
wild-type and nucleophile mutant (E343Q) HPSE each in com-
plex with ABP 5. Complexes of HPSE with 5 were similar to 
those obtained with AcGH79, showing a single molecule of 
probe occupy-ing the −1 subsite of the HPSE substrate-binding 
cleft (nomencla-ture according to ref. 40) in reacted 4C1 (wild-
type) or in unreacted 4H3 (mutant) conformations (Supplementary 
Fig. 8a). The network of interactions made with the probe was 
highly similar between AcGH79 and HPSE, with the primary 
difference being a lack of inter-action from HPSE to O4 of the 
probe, as the natural HS substrate of HPSE extends toward this 
position (Supplementary Fig. 8b). A −1 subsite C6 carboxylate 
recognition motif, comprising three hydrogen bonds from a tyrosine 
and two consecutive backbone amides, is highly conserved in GH79 
β-glucuronidases (Tyr 334 and Gln293–Gly294 in AcGH79; Tyr391 
and Gly349–Gly350 in HPSE; Tyr302 and Gly261–Gly262 in the 
recently characterized heparanase from Burkholderia 
pseudomallei)41. This strong network of hydrogen bonds to the C6 
carboxylate likely offsets the absence of only a single hydrogen 
bond to O4 of the ABP in HPSE com-pared to AcGH79, thus 
rationalizing robust labeling of HPSE by a monosaccharide probe 
that only occupies a single subsite within its extensive substrate-
binding cleft. Additional binding affinity may also derive from the 
transition-state-like 4H3 conformation adopted by unreacted ABPs.  
We next sought to solve the structure of proHPSE to 
character-ize the basis of its ‘inactivation’ by the 6-kDa linker 
peptide and to determine how β-glucuronidase ABPs are able to 
circumvent this. Herein, we report the first crystal structure of 
proHPSE in both apo and ABP-complexed forms, which, 
together with previously reported HPSE structures, completes a 
structural characterization of the HPSE maturation process.  
The proHPSE structure was similar to that of mature HPSE 
(r.m.s. deviation: 0.52 Å over 451 Cα), with the same ( β/α)8 and β-
sheet domains clearly discernible. The 6-kDa linker (residues 110–
157) forms a large helical domain, which sits directly ‘above’ the 
active site cleft, blocking access to the bulky HS substrates of HPSE. 
The final loop of the linker leading into the 50-kDa subunit 
(His155–Lys159) is substantially more disordered than the rest of 
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Figure 5 | Three-dimensional structure of proHPSE, and its 
  
Figure 4 | General and endo-specific inhibition of b-glucuronidases as 
assessed by competitive ABP profiling. (a) Monosugar like β-
glucuronidase inhibitor siastatin b can be accommodated exo- and endo-
acting β-glucuronidase active sites, and competes out Abp 3 labeling of 
both GuSb and HpSe. (b) polysaccharide heparin (12) only inhibits Abp 
labeling of HpSe, because of its inability to interact with the exo-configured 
active site of GuSb. (c) Selective HpSe inhibition is also achieved by 
heparan sulfate (13). competitive Abp gels shown are representative of 
three technical replicates. plots are mean values ± s.d. (N = 3) for 
quantitated HpSe and GuSb fluorescent band intensities, normalized to 
band intensities in the no inhibitor control lane. For all plots, quantitated 
GuSb fluorescence is a sum of the three assigned bands. n.d., not 
determined. 
active site interactions with ABP 5. (a) Ribbon and surface diagram 
of proHpSe demonstrating steric blockage of the HpSe binding cleft by 
the 6 kda linker. An exposed ‘pocket’ in proHpSe can still interact with 
small molecules such as 5 (highlighted pink). (b) Abp 5 in complex with 
proHpSe within its ‘binding pocket’. the o4 position, where 
 
HS substrates would extend in mature HpSe, is blocked by His155, 
contributed by the linker (colored in green). density is ReFMAc 
maximum-likelihood/σA weighted 2Fo − Fc contoured to 0.38 electrons/Å3. 
(c) Schematic of hydrogen bonding interactions between reacted 5 and 
proHpSe active site residues. interactions are identical to those observed 
for the mature enzyme (Supplementary Fig. 8a,b), 
 
except for His155 proximal to o4 of the probe. nuc., 
nucleophile; a/b, acid/base. 
  
the linker, as evidenced by higher B factors for these residues in 
the crystallographic model (Supplementary Fig. 9a,b). 
Mutation stud-ies have established Tyr156 of the proHPSE 
linker as being criti-cal for recognition by CTSL in the first step 
of HPSE maturation42. Disorder of the His155–Lys159 loop 
allows for unencumbered CTSL access to Tyr156 without 
disrupting pre-existing second-ary structures, consistent with the 
important role of Tyr156 in HPSE maturation. 
Unexpectedly, steric blockage by the linker peptide was found to be 
incomplete in proHPSE, leaving a ‘binding pocket’ on the pro-tein 
surface containing exposed catalytic nucleophile and acid/base residues, 
similar to the exo-acting active site of AcGH79 (Fig. 5a). When 
compared in a sequence alignment, the proHPSE linker corre-sponds to 
a loop in AcGH79 that forms the ‘rear’ face of its active site pocket, 
suggesting that although this sequence has expanded in the human 
enzyme, proHPSE still retains some structural characteristics 
reminiscent of a GH79 exo-glycosidase (Supplementary Fig. 8c). ABP 
5 was found to bind to this proHPSE ‘active site pocket’ in a 
configuration identical to that observed for HPSE. The O4 proxi-mal 
position, which is vacant in HPSE, was occupied by His155 (contributed 
by the linker) in proHPSE, which blocks off extension toward this 
position by HS substrates (Fig. 5b,c). The disordered proHPSE loop, 
His155–Lys159, was slightly displaced upon binding 5 (~1.5 Å for 
Tyr156 Cα), reflecting steric clashes with the bound ABP 
(Supplementary Fig. 9c).  
ProHPSE, as with the mature HPSE, was inactive against the 
artificial fluorogenic substrate 4MU-GlcUA, indicating that it does 
not possess any additional exo-glucuronidase activity against this 
substrate, which is lost upon maturation (Supplementary Fig. 8d). 
To assess the accessibility of the proHPSE ‘pocket’ compared to 
 
mature HPSE, we conducted competitive ABP experiments against 
recombinant proHPSE and HPSE using 3. As seen in platelet lysates, 
siastatin B inhibited ABP labeling of both proHPSE and mature 
HPSE (Supplementary Fig. 10a), indicating that it could efficiently 
occupy the ‘binding pocket’ of proHPSE as well as HPSE. By 
contrast, heparin only inhibited labeling of HPSE, albeit with lower 
efficacy than that seen in platelets, possibly due to more facile ABP 
labeling of the recombinant enzyme. Unexpectedly, proHPSE 
labeling was slightly increased at moderate heparin concentrations 
(Supplementary Fig. 10b). Finally, we tested the ability of GlcUA 
to inhibit labeling of HPSE and proHPSE. No substantial inhibition 
of either proHPSE or HPSE labeling was observed at up to 20 mM 
GlcUA (Supplementary Fig. 10c), suggesting that GlcUA cannot 
occupy the active site of proHPSE or HPSE with sufficient affin-ity 
to prevent binding and reactivity of an ABP. Further subsite 
interactions may be required for binding of simple glucuronides to 
proHPSE or HPSE.  
It has previously been demonstrated that proHPSE uptake by 
cells is a HS-dependent process and can be disrupted by addi-
tion of exogenous heparin43. To investigate possible roles for the 
proHPSE ‘binding pocket’ in proHPSE uptake and maturation, 
we prelabeled recombinant proHPSE with either untagged ABP 
6, fluorescent ABPs 1 or 3, or a mock DMSO control, and 
examined its uptake by fibroblasts at 90 or 180 min. In all cases, 
prelabeled proHPSEs were taken up and processed to mature 
HPSE, as evi-denced by western blot and fluorescence of 
internalized 1 or 3 (Supplementary Fig. 11). These data indicate 
that the proHPSE ‘pocket’ does not participate in the HS 
interactions involved in cel-lular uptake and that occupation of 
the proHPSE ‘pocket’ does not inhibit HPSE maturation. 
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DIScUSSION 
The important role of β-glucuronidases in human biology is high-
lighted by the pathologies associated with aberrant expression of 
these enzymes. Lack of GUSB activity leads to accumulation of 
glucuronide-containing GAGs within lysosomes in MPSVII (Sly 
syndrome). Conversely, overexpression of HPSE leads to aberrant 
breakdown of HS in the ECM, causing increased cancer growth and 
metastasis. Accurate tracking of β-glucuronidase activities is an 
essential prerequisite for fully understanding the role of these 
enzymes in both physiological and disease states.  
Here we have reported the design and application of new β-
glucuronidase-configured ABPs and demonstrated their broad 
utility for interrogating the activities of these enzymes. We show 
that ABP profiling is a viable method to assay β-glucuronidase 
activity in a variety of samples, ranging from recombinant 
proteins to complex cell, tissue, and organ lysates. Fluorescence 
labeling provides a facile method to probe β-glucuronidases in 
tissues with sufficient expression, allowing tracking of processes 
such as proen-zyme uptake and processing and how these are 
affected by biologi-cal or pharmacological perturbation. In 
tissues with lower enzyme abundance, we have demonstrated 
detection of β-glucuronidases using a proteomic approach, which 
is also applicable for the dis-covery of previously 
uncharacterized β-glucuronidase activities in biological samples.  
Use of ABPs provides several advantages over more traditional 
methods to quantitate glycoside hydrolase activities. Compared to 
techniques such as western blotting, ABPs specifically detect active 
enzymes rather than an entire protein complement that may include 
misfolded or inactive isoforms. Although fluorometric or colori-
metric assays also provide assessments of enzyme activity, they can-
not distinguish between overlapping activities in complex mixtures, 
which arise from several enzymes or enzyme isoforms active on the 
same substrate. Indeed, many carbohydrate-processing enzymes are 
processed from precursors into one or more isoforms that have dif-
fering activities on the same substrate23,28,44,45. ABP profiling allows 
multiple overlapping activities to be visualized and their responses 
to perturbation or inhibition to be individually assessed in situ.  
Many endo-glycosidases such as HPSE are inactive in traditional 
activity assays, necessitating the use of expensive specialized sub-strates 
and/or cumbersome assay procedures to follow their activi-ties. The 
discovery that aziridine ABPs label HPSE paves the way for more rapid 
and practical methods to assess the activity of this enzyme, and may 
inspire development of probes to assay other endo-glycosidases. 
Although this current generation of β-glucuronidase ABPs shows some 
off-target effects against GBA and GLB1, limiting their use in 
diagnostic applications, further optimization based upon the crystal 
structures of HPSE (and proHPSE) may lead to improved probes with 
increased potency and specificity. Optimization efforts will be aided by 
the use of competitive ABP techniques, which we have demonstrated to 
be viable methods for assessing selective inhibitors of individual β-
glucuronidases.  
ABPs also provide powerful tools for the characterization of 
novel enzyme activities that may escape detection in traditional bio-
chemical experiments. The use of an ABP-driven approach in this 
study lead us to the surprising observation that the HPSE precursor 
proHPSE is, in principle, catalytically competent, an entirely unan-
ticipated outcome based on previous studies. We have reported the 
first structural views of proHPSE, illustrating how its 6-kDa linker 
restricts access to the active site cleft for HS substrates. This linker 
does not entirely block access to the catalytic residues of proHPSE, 
but instead contributes to the formation of an exo-glycosidase-like 
‘binding pocket’ that can accommodate smaller molecules. It 
remains to be determined whether this proHPSE ‘pocket’ is simply a 
structural relic from evolutionary expansion of an ancestral GH79 
active site loop or if there are bona fide endogenous substrates that 
can be hydrolyzed by proHPSE. 
 
In conclusion, we have presented a set of ABPs for functional 
interrogation of β-glucuronidases in their native contexts. The 
application of ABP methodology to carbohydrate-processing 
enzymes provides a powerful set of tools to study the activity of 
these key enzymes and will contribute toward our understanding 
of fundamental processes in glycobiology. 
 
 
 
 
mETHODS 
Methods, including statements of data availability and any 
associated accession codes and references, are available in the 
online version of the paper. 
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ONLINE mETHODS  
Chemical probes and inhibitors. 4MU-GlcUA, leupeptin, siastatin B, hyaluronic 
acid (15) and chondroitin sulfate (16) were obtained from Sigma-Aldrich. CTSL 
inhibitors CAA0225 (10) and Z-FY(tBu)-DMK (11) were obtained from Merck. 
Heparin (12) and heparan sulfate (13) were obtained from Iduron. N-Acetyl-O-
desulfated heparin (14) was obtained from Dextra. Cyclophellitol, cyclophellitol 
aziridine and ABP 9 were synthesized according to described procedures12,46. 
Syntheses of compounds 1–8 are described in Supplementary Note 2. 
 
Tissue and cell samples. Patients with Gaucher disease were diagnosed on 
the basis of reduced GBA activity and demonstration of an abnormal 
genotype. Spleens from a healthy subject and a patient suffering from type 1 
Gaucher dis-ease were collected after splenectomy and frozen at −80 °C until 
use. Platelets were collected from healthy donors, using EDTA as the anti-
coagulant. Platelet-rich plasma (PRP) was prepared by centrifugation at 100g 
for 20 min at 22 °C to remove red and white blood cells. Platelets were 
isolated from PRP by centrifugation at 220g for 10 min at 22 °C and frozen 
at −80 °C until use. Approval for tissue collection was obtained from the 
Academisch Medisch Centrum (AMC) and University of York medical 
ethics committees. Informed consent was obtained from all donors. 
 
Primary human fibroblasts (CC-2511) were obtained from Lonza. 
HEK293T cells (ATCC -CRL-3216) were obtained from the American Type 
Culture Collection (ATCC). Sf21 and High Five cells for protein pro-duction 
were obtained from Invitrogen. Cells were used as obtained from the supplier 
without further authentication. All cells used tested negative for mycoplasma 
contamination.  
All tissue lysates were prepared in KPI buffer (25 mM potassium phosphate 
(pH 6.5) supplemented with 1× cOmplete protease inhibitor cocktail (Roche)). 
Cells/tissues were homogenized with a silent crusher S equipped with a type 7 F/S 
head (30,000 r.p.m.; 3 × 7 s) on ice. Lysate protein concentrations were 
determined with a Qubit 2.0 Fluorometer (Invitrogen) or Bradford assay using 
BSA as a standard. Lysates were stored in aliquots at −80 °C until use. 
 
Recombinant protein cloning, expression and purification. AcGH79. The 
coding sequence of AcGH79 with an N-terminal 6× His tag was cloned into 
pET28a (Novagen), which was used to transform E. coli BL21-Gold(DE3) 
(Agilent). Transformants were grown at 37 °C in LB media containing 50 μg/ml 
kanamycin to an OD600 of 0.8, induced by addition of 1 mM isopropyl β-D-1-
thiogalactopyranoside, and protein production carried out at 25 °C for 12 h. 
Harvested cells were resuspended in 50 ml AcGH79 HisTrap buffer A (20 mM 
HEPES (pH 7.0), 200 mM NaCl, 5 mM imidazole), lysed by sonication, and lysate 
clarified by centrifugation at 12,000g. Supernatant containing AcGH79 was 
filtered before loading onto a HisTrap 5 ml FF crude column (GE Healthcare) pre-
equilibrated with AcGH79 HisTrap buffer A. The loaded HisTrap column was 
washed with 10 column volumes (CV) of AcGH79 HisTrap buffer A, before 
eluting with AcGH79 HisTrap buffer B (20 mM HEPES (pH 7.0), 200 mM NaCl, 
400 mM imidazole) over a 20 CV linear gradient. 
 
Fractions containing AcGH79 were pooled, concentrated using a 30-kDa 
cutoff Vivaspin concentrator (GE Healthcare) and further purified by size-
exclusion chromatography (SEC) using a Superdex 75 16/600 column (GE 
Healthcare) in AcGH79 SEC buffer (20 mM HEPES (pH 7.0), 200 mM 
NaCl). Fractions containing AcGH79 were pooled and concentrated using a 
30 kDa Vivaspin concentrator to a final concentration of 14.5 mg/ml, and 
flash frozen for use in further experiments. 
 
E287Q mutagenesis was carried out using a PCR- based method47. Mutant 
protein was purified using the same protocol as for wild-type protein. 
Mutagenesis primers are listed in Supplementary Table 2. 
Mature HPSE. Mature HPSE cloning, expression, and purification was 
carried out as previously described8. 
E343Q mutagenesis was carried out using a PCR-based method. Mutant 
pro-tein was purified using the same protocol as for wild-type protein. 
Mutagenesis primers are listed in Supplementary Table 2. 
proHPSE. Insect cells are unable to process proHPSE to mature HPSE, 
allowing the former to be isolated following expression. cDNA encoding 
proHPSE, minus the first 35 amino acid codons comprising the native signal 
sequence, was cloned behind a 5′ honeybee mellitin signal sequence, 6× His 
 
tag, and TEV cleavage site, into the pOMNIBac plasmid (Geneva Biotech) 
using SLIC48. pOMNIBac-proHPSE was used to generate recombinant 
bacmid using the Tn7 transposition method in DH10EMBacY cells49 
(Geneva Biotech). Baculovirus preparation and protein expression was 
carried out as previously described for mature HPSE8.  
For purification, 3 l of conditioned media was cleared of cells by centrifu-
gation at 400g for 15 min at 4 °C, followed by further clearing of debris by 
centrifugation at 4,000 g for 60 min at 4 °C. DTT (1 mM) and AEBSF (0.1 mM) 
were added to cleared media, which was loaded onto a HiTrap Sepharose SP 
 
FF 5 ml column (GE healthcare) pre-equilibrated in IEX buffer A (20 mM 
HEPES (pH 7.4), 100 mM NaCl, 1 mM DTT). The loaded SP FF column 
was washed with 10 CV of IEX buffer A, and eluted with a linear gradient 
over 30 CV using IEX buffer B (20 mM HEPES (pH 7.4), 1.5 M NaCl, 1 
mM DTT). proHPSE-containing fractions were pooled and diluted 10-fold 
into proHPSE HisTrap buffer A (20 mM HEPES (pH 7.4), 500 mM NaCl, 20 
mM Imidazole, 1 mM DTT), before loading onto a HisTrap 5 ml FF crude 
column pre-equilibrated in proHPSE HisTrap buffer A. The loaded HisTrap 
column was washed with 10 CV HisTrap buffer A and eluted with a linear 
gradi-ent over 20 CV using proHPSE HisTrap buffer B (20 mM HEPES (pH 
7.4), 500 mM NaCl, 1 M Imidazole, 1 mM DTT). proHPSE-containing 
fractions were pooled and concentrated to ~2 ml using a 30 kDa cutoff 
Vivaspin con-centrator, and treated with 5 μl EndoH (NEB) and 5 μl AcTEV 
protease (Invitrogen) for >72 h. Digested protein was purified by SEC using 
a Superdex S75 16/600 column in proHPSE SEC buffer (20 mM HEPES (pH 
7.4), 200 mM NaCl, 1 mM DTT). proHPSE containing fractions were 
concentrated to 10 mg/ml using a 30 kDa Vivaspin concentrator, exchanged 
into IEX buffer A via at least three rounds of dilution–re-concentration and 
flash frozen for use in further experiments. 
 
Overexpression of HPSE in HEK293T cells. pGEn1-HPSE and pGEn2-HPSE 
plasmids were obtained from the DNASU repository50. HEK293T cells were 
grown in DMEM media supplemented with 10% newborn calf serum (NBCS; 
Sigma) and 1% penicillin/streptomycin (Sigma). 20 μg DNA was transfected into 
HEK293T cells grown to ~80% confluence, using linear PEI at a ratio of 3:1 
(PEI:DNA). At relevant time points cells were washed with PBS, harvested into 
KPI buffer using a cell scraper, and pelleted by centrifugation at 200g for 5 min at 
4 °C. Cell pellets were frozen at −80 °C before use. 
 
For CTSL inhibition experiments, transfections were carried out as above, 
except media was exchanged 7 h post transfection for DMEM supplemented 
with CTSL inhibitor or vehicle-only control (0.05% v/v EtOH). 
 
proHPSE fibroblast uptake experiment. Primary human fibroblasts were 
grown in DMEM/F12 media supplemented with 10% NBCS and 1% 
penicillin/ streptomycin. Cells at 80% confluence were washed with PBS, 
before exchang-ing into DMEM/F12 media supplemented with 10% NBCS, 
1% penicillin/ streptomycin and 10 μg/ml proHPSE. At relevant time points, 
cells were washed with ice cold PBS twice, harvested into KPI buffer using a 
cell scraper, and pelleted by centrifugation at 200 g for 5 min at 4 °C. Cell 
pellets were stored at −80 °C before use.  
For uptake experiments with prelabeled proHPSEs, prelabeling was 
carried out in McIlvaine citrate/phosphate buffer (pH 5.0), 300 mM NaCl in 
200 μl volume, using 50 μM proHPSE and 200 μ M ABP. Reactions were 
incubated for 1 h for 37 °C, then excess ABP removed by desalting using a 
40 kDa MWCO Zeba spin column (Thermo). Extent of prelabeling by 1 and 
3 was directly quantified by comparison of protein and fluorophore UV- 
visible absorption values. Extent of prelabeling by 6 was estimated by testing 
residual reactivity to 3 (Supplementary Fig. 11b). 
 
Enzyme activity and inhibition assays. Recombinant AcGH79 enzyme activ-ity 
was assayed using 1.67 ng protein in 150 mM McIlvaine buffer (pH 5.0). To 
determine apparent IC50 values, 25 μl AcGH79 was preincubated with a range of 
inhibitor dilutions for 30 min at 37 °C, followed by addition of 100 μl 4MU-
GlcUA solution to give final concentrations of 260 pM AcGH79 and 2.5 mM 
4MU-GlcUA. Reactions were carried out for 30 min at 37 °C, quenched with 200 
μl of 1 M NaOH-glycine (pH 10.3), and 4-MU fluorescence meas-ured using a 
LS55 Fluorometer (PerkinElmer) at λex 366 nm and λem 445 nm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Apparent IC50 values were determined in Prism (GraphPad) using a one 
phase exponential decay function.  
Kinetic parameters for inhibition of AcGH79 were determined using a 
continuous method (Supplementary Note 1; ref. 20). AcGH79 was added to 
pre-warmed mixtures of 4MU-GlcUA and ABP, to give final concentrations 
of 260 pM AcGH79 and 2.5 mM 4MU-GlcUA in a final reaction volume of 
165 μl. Reactions were incubated at 37 °C. At set time points, aliquots of 
reac-tion mixture were transferred to 96-well microplates (Greiner) and 
quenched with 1 M NaOH-glycine (pH 10.3), and 4MU fluorescence was 
measured immediately using a LS-55 Fluorometer. The apparent rate of 
inactivation (kobs) was calculated for each ABP concentration by fitting with 
the exponential function 4MU fluorescence = A*(1–e^(−kobs*t)) . The 
resulting plots of kobs vs. [ABP] were fitted using a linear function, which 
gives the combined apparent inhibition parameter ki/K′I as the gradient. ki/KI 
was derived from ki/K′ I by correcting for the presence of competing 4MU-
GlcUA substrate, using the relationship K′I = KI (1+[S]/KM ), where [S] = 2.5 
mM and KM = 18.2 μM. All fittings were carried out using Prism.  
In situ fibroblast IC50s were determined by incubating human fibroblast 
cells with a range of inhibitor dilutions for 2 h, followed by 3× washing with 
PBS and harvesting into KPI buffer supplemented with 0.1% Triton X- 100. 
Harvested cells were pelleted by centrifugation at 200 g for 5 min at 4 °C, 
and pellets stored at −80 °C before use. Enzymatic reactions and apparent 
IC50 calculations were performed as described for the in vitro IC50 
determination experiments, but with 5 μg of total lysate protein per reaction. 
 
Fluorescence labeling. Initial labeling reactions were carried out in McIlvaine 
buffer (pH 5.0), except for pH range experiments, which were carried out in 
McIlvaine buffer at the stated pHs. Typically 200 fmol recombinant protein was 
used for labeling AcGH79, HPSE and proHPSE (20 nM in 10 μl final reac-tion 
volume). 20 μg total protein was used for labeling cell and tissue lysates, except 
for HEK293T overexpression experiments, where 10 μg total protein was used. 
Unless otherwise specified, labeling reactions were carried out by incubation with 
100 nM fluorescent ABP in a reaction volume of 10 μl for 1 h at 37 °C. Gels were 
scanned for ABP-emitted fluorescence using a Bio-Rad ChemiDoc MP imager 
with the settings: Cy2 (λEX 470 nm, bandpass 30 nm; λEM 530 nm, bandpass 28 
nm) for 1, Cy3 (λEX 530 nm, bandpass 28 nm; λEM 605 nm, bandpass 50 nm) for 
2, and Cy5 (λEX 625 nm, bandpass 30 nm; λEM 695 nm, bandpass 55 nm) for 3. 
 
For labeling rate experiments with pro- and mature HPSE, reactions were 
carried out as above, except 2 pmol recombinant protein was incubated with 
an equimolar amount of 3 at 37 °C. At specified time points, aliquots were 
removed from the reaction and denatured by boiling in Laemmli buffer. 
Denatured samples were stored on ice until all time points were collected, 
and run together on SDS–PAGE.  
For competition experiments, optimized labeling reactions were carried out in 
McIlvaine buffer (pH 5.0), 300 mM NaCl. Protein samples were pre-incubated 
with inhibitor for 60 min at 37 °C before addition of 100 nM 3 for labeling. 
Platelet lysates were labeled at 37 °C for 1 h, recombinant proteins were labeled at 
37 °C for 30 min. Following labeling, samples were denatured by boiling with 
Laemmli buffer for 5 min, and resolved by SDS–PAGE. Gels used for quantitation 
were scanned using a laser based Bio-Rad FX molecular imager, using the λEX 
635 nm external laser and 690BP emission filter. Images were analyzed using 
Quantity One (Bio-Rad). Full-length images of all fluores-cent gels used in this 
study can be found in Supplementary Figure 12. 
 
Chemical proteomics. 3 mg total protein from human wild-type spleen, Gaucher 
spleen lysate, or human fibroblast lysate was incubated with either 10 μM 4, 10 
μM 9 for 30 min followed by 10 μM 4, or a vehicle-only con-trol (0.1% DMSO). 
All labeling reactions were carried out for 30 min at 37 °C in 500 μl McIlvaine 
buffer (pH 5.0), before denaturation by addition of 125 μl 10% SDS and boiling 
for 5 min. Samples were prepared for pulldown with streptavidin coupled 
DynaBeads (Invitrogen) as described previously51. Following pulldown the 
samples were divided: 1/3 for in-gel digest and 2/3 for on-bead digest. In-gel 
digest samples were eluted by boiling beads at 100 °C in 30 μl Laemmli buffer. 
Eluted proteins were separated by SDS–PAGE and visualized by silver staining 
using the SilverQuest kit (Invitrogen). Bands were 
excised by scalpel and treated with gel-digestion buffer (10 mM NH4HCO3, 
5% ACN, 1mM CaCl2, 10 ng/μl trypsin) at 37 °C overnight. The resulting 
trypsin-digested peptides were desalted using stage tips, followed by 
evaporation of ACN and resuspension into 70 μl sample solution (95:3:0.1 of 
H2O:ACN:TFA) for LC–MS analysis. Samples were analyzed with a 2 h 
gradient of 5–25% ACN on a nano-LC, hyphenated to an LTQ-Orbitrap. 
Peptides were identified via the Mascot protein search engine. 
On-bead digest samples were treated with trypsin digestion buffer (100 mM 
Tris (pH 7.8), 100 mM NaCl, 1 mM CaCl2, 2% ACN and 10 ng/μl trypsin) at 37 
°C overnight with shaking. Trypsin-digested peptides were desalted using stage 
tips, and analyzed as above. For identification of GUSB active site pep-tides, 
trypsin digested beads were further treated with endoproteinase Glu-C digestion 
buffer (100 ng/μl Glu-C in PBS) at 37 °C overnight with shaking. Digested 
peptides were desalted and analyzed as above. 
 
Peptide identification data were stringently filtered at a false discovery rate 
(FDR) of 1% and an MS/MS assignment Mascot score >40. Full proteomics data 
are available in Supplementary Data Set 1, which shows: the ranking of the 
proteins by the protein score, the UniProt accession number, trivial name of the 
protein, protein score, protein mass predicted from the RNA sequence, the amino 
acid coverage of the protein achieved by MS/MS sequencing, the query number of 
the peptide in the LC–MS run, the experimentally determined m/z of the peptide, 
the measured molecular weight, the charge state z, the predicted molecular weight, 
the delta accuracy between predicted and experimentally determined mass, the 
MS/MS assignment Mascot score, the expectancy value, peptide sequence and 
emPAI value (which gives an approximate relative esti-mation of peptide 
abundance). 
 
Western blotting. Proteins resolved by SDS–PAGE were transferred to a PVDF 
membrane using a Trans-Blot Turbo system (Bio-Rad). Membranes were blocked 
in 5% BSA for 1 h at room temperature, then incubated with anti-HPSE (AbCam; 
ab59787) or anti-GUSB (AbCam; ab103112) at 1:1,000 dilu-tion in 5% BSA at 4 
°C overnight. Membranes were washed 3× with TBST (50 mM Tris (pH 7.5), 150 
mM NaCl, 0.05% Tween 20), then incubated with HRP-conjugated goat anti-
rabbit (Sigma; A0545) at 1:5,000 dilution in 5% BSA for 1 h at room temperature. 
Membranes were washed again 3× with TBST, and blots visualized using 
Amersham prime ECL reagent (GE Healthcare) and recorded using a Bio-Rad 
ChemiDoc XRS. Full-length images of all blots used in this study can be found in 
Supplementary Figure 12. 
 
Protein crystallization. AcGH79. AcGH79 was tested against a range of 
com-mercial crystallization screens. Well diffracting crystals of wild-type 
AcGH79 were obtained by the sitting-drop vapor-diffusion method at 20 °C 
using 0.8–1.2 M of 0.5:9.5 NaH2PO4:K2HPO4 (v/v) at a protein:well ratio of 
700:500 nl. Crystals of AcGH79 E287Q mutant were obtained using 1.2–1.5 
M of 1.0:9.0 NaH2PO4:K2HPO4 (v/v) at a protein:well ratio of 500:500 nl. 
Crystals typically appeared after 1 d. Crystals were cryoprotected using 2 M 
lithium sulfate before flash freezing in liquid N2 for data collection.  
Mature HPSE. Mature HPSE was crystallized and data collected as previ-
ously described8.  
proHPSE. proHPSE at 10 mg/ml was tested against a range of commercial 
crystallization screens. Thin plate crystals were found in the JCSG screen, 
which were used to microseed subsequent rounds of crystal screening52. Well 
diffract-ing single crystals were obtained by the sitting drop vapor diffusion 
method at 20 °C using 100 mM succinate (pH 7.0), 17% PEG3350 and 1:250 
diluted seed stock at a protein:seed:well ratio of 700:100:400 nl. Crystals 
typically appeared after 1 d and grew to maximum size within 10 d. proHPSE 
crystals were cryo-protected using mother liquor solution supplemented with 
25% ethylene glycol before flash freezing in liquid N2 for data collection. 
 
X-ray data collection and structure solution. Xray diffraction data were collected at 
100 K at beamlines i02 (5LA4, 5LA7), i03 (5G0Q, 5L77, 5L9Y) and i04 (5L9Z) of the 
Diamond Light Source UK. Reflections were autoprocessed with the xia2 pipeline53 of 
the CCP4 software suite, or manually processed using XDS54 and Aimless55. Apo-
proHPSE was solved by molecular replacement with the mature HPSE model (5E8M) 
using MolRep56, followed by alternating rounds of manual model building and 
refinement using Coot and REFMAC5, respectively57,58. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For all complexes with ABP 5, crystals were soaked in their respective 
mother liquors supplemented with 2–5 mM 5 for 1–3 h at 20 °C. Soaked 
crystals were cryoprotected using their respective cryoprotectant solutions 
before flash freezing in liquid N2 for data collection.  
Complexes were solved by molecular replacement with their respective 
apo structures, followed by rounds of manual model building and refinement 
using Coot and REFMAC5. Ligand coordinates were built using jLigand59. 
Active site diagrams were generated using ccp4mg60. Ribbon and protein 
surface diagrams were generated using PyMOL. 
 
Data availability. All data generated or analyzed during this study are included in 
this published article (and its Supplementary Information files), or are avail-able 
from the corresponding authors on reasonable request. Coordinates and structure 
factors have been deposited in the Protein Data Bank under acces-sion codes 
5G0Q (AcGH79(wt)–5 complex), 5L77 (AcGH79(E287Q)–5 com-plex), 5L9Y 
(HPSE(wt)–5 complex), 5L9Z (HPSE(E343Q)–5 complex), 5LA4 (apo-
proHPSE), 5LA7 (proHPSE–5 complex). 
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